skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation

(2057) Views  (528) Full article downloads

Authors: Paolo Gelosa, Mauro Cimino, Alice Pignieri, Elena Tremoli, Uliano Guerrini, et al

Published Date November 2007 Volume 2007:3(5) Pages 567 - 577
DOI: http://dx.doi.org/10.2147/VHRM.S

Paolo Gelosa1, Mauro Cimino2, Alice Pignieri1, Elena Tremoli1,3, Uliano Guerrini1, Luigi Sironi1

1Department of Pharmacological Sciences, University of Milan, Italy; 2Institute of Pharmacological Sciences, Carlo Bo University of Urbino, Italy; 3Monzino Cardiologic Center IRCCS, Milan, Italy

Abstract: Statin-induced inhibition of HMG-CoA reductase reduces cholesterol production and prevents the formation of many non-steroidal isoprenoid compounds, such as farnesylpyrophosphate and geranylgeranylpyrophosphate, that act as lipid attachments for the post-translational modification of various proteins, including the G-proteins and transcription factors involved in a number of cell processes. However, the blockade of isoprenylation elicited by statin treatment also has biological effects on cell function that go beyond the decrease in cholesterol synthesis: these are the so-called “pleiotropic” effects that mainly relate to vascular function. Endothelial dysfunction is an independent predictor of cardiovascular events that correlates with inflammation markers/mediators and robust predictors of cardiovascular diseases such as increased high-sensitivity C-reactive protein levels. The results of in vivo and in vitro studies indicate that the statins have beneficial effects unrelated to cholesterol lowering, such as improving endothelial function, increasing myocardial perfusion, and enhancing the availability of nitric oxide. This review describes the pleiotropic effects of statins that may be involved in modulating/preventing endothelial dysfunction and inflammatory processes, as well as the cellular and molecular mechanisms through which they improve endothelial function.

Keywords: statins; inflammation; endothelial dysfunction; nitric oxide; HMG-CoA reductase








Readers of this article also read:

Emergency endovascular repair of acute descending thoracic aortic dissection
Are pleiotropic effects of statins real?
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Corrigendum
Primary care for diabetes mellitus: perspective from older patients
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University